Prostatype Genomics AB (publ) (OM: PROGEN)
Health Care · Biotechnology · SE
Skr0.10
+13.29% today · -85.2% 1Y
Prostatype Genomics AB (publ) (OM: PROGEN) operates in the Biotechnology industry within the Health Care sector. The company is valued at $7.26M and employs 7 people.
Over the last twelve months the share price has lost 85.2%, trading between 0.08 and 2.28.
Tweenvest scores Prostatype Genomics AB (publ) across four factors: quality 28/100, value 65/100, growth 0/100. Its strongest factor is value.
PROGEN price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $7.26M
- Revenue (TTM)
- $83.06K
- P/E
- —
- EPS
- -0.69
- Dividend yield
- —
- Beta (5Y)
- 1.42
- 52-week high
- Skr2.28
- 52-week low
- Skr0.08
- Avg volume (3M)
- —
- Shares outstanding
- 691.32M
- Employees
- 7
- Next earnings
- —
About Prostatype Genomics AB (publ)
Prostatype Genomics AB focuses on creating, marketing, and selling sophisticated prognostic gene tests. Their primary offering, the Prostatype Test System, combines genetic expression data with key clinical measurements such as PSA levels, Gleason Score, and Tumor Stage to determine a specific P-score. This advanced diagnostic tool is built upon a vast database of prostate cancer patients, providing crucial support for patients and medical practitioners when deciding on treatment strategies. Founded in 2007, the company is headquartered in Solna, Sweden.
- ISIN
- SE0023261532
- Founded
- 2007
- Listed since
- Nov 3, 2020
- Exchange
- OMX Nordic Exchange Stockholm
- Currency
- SEK
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Ascelia Pharma AB (publ)OM: ACE | $7.58M | Skr0.56 | -34.65% |
| Aprea Therapeutics, Inc.NasdaqCM: APRE | $7.36M | $0.58 | -3.34% |
| Exicure, Inc.NasdaqCM: XCUR | $7.33M | $1.12 | +6.67% |
| Oncodesign Precision Medicine Société anonymeENXTPA: ALOPM | $7.30M | €0.34 | +3.33% |
| Zeo ScientifiX, Inc.OTCPK: ZEOX | $7.14M | $0.91 | -23.11% |
| Senti Biosciences Holdings, Inc.NasdaqCM: SNTI | $7.00M | $0.22 | -28.47% |
| Rakovina Therapeutics Inc.TSXV: RKV | $6.93M | CA$0.22 | -2.22% |
| Skye Bioscience, Inc.NasdaqCM: SKYE | $6.86M | $1.55 | -8.28% |
Figures last refreshed Oct 18, 2026.